- Home
- NUVL
NUVL
Nuvalent Inc.
as of 03-06-2026 3:53pm EST
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 8.1B | IPO Year: | 2021 |
| Target Price: | $135.33 | AVG Volume (30 days): | 443.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.85 | EPS Growth: | -48.85 |
| 52 Week Low/High: | $55.53 - $113.02 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1064.25% |
| P/E Ratio: | -17.10 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered NUVL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Nuvalent Inc. (NUVL)
Chief Legal Officer
Avg Cost/Share
$103.34
Shares
5,500
Total Value
$566,787.54
Owned After
62,436
Chief Development Officer
Avg Cost/Share
$103.44
Shares
5,500
Total Value
$566,682.00
Owned After
58,117
Chief Development Officer
Avg Cost/Share
$102.20
Shares
5,500
Total Value
$561,422.05
Owned After
58,117
Chief Legal Officer
Avg Cost/Share
$110.16
Shares
14,300
Total Value
$1,575,288.00
Owned After
62,436
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$109.84
Shares
700
Total Value
$76,888.00
Owned After
62,436
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$97.49
Shares
2,589
Total Value
$251,559.68
Owned After
62,436
Chief Development Officer
Avg Cost/Share
$97.49
Shares
3,181
Total Value
$309,081.30
Owned After
58,117
Chief Financial Officer
Avg Cost/Share
$97.49
Shares
3,181
Total Value
$309,081.30
Owned After
81,733
Chief Medical Officer
Avg Cost/Share
$97.49
Shares
3,181
Total Value
$309,081.30
Owned After
55,355
President and CEO
Avg Cost/Share
$97.49
Shares
9,543
Total Value
$927,243.90
Owned After
284,209
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Miller Deborah Ann | NUVL | Chief Legal Officer | Feb 26, 2026 | Sell | $103.34 | 5,500 | $566,787.54 | 62,436 | |
| Noci Darlene | NUVL | Chief Development Officer | Feb 26, 2026 | Sell | $103.44 | 5,500 | $566,682.00 | 58,117 | |
| Noci Darlene | NUVL | Chief Development Officer | Jan 29, 2026 | Sell | $102.20 | 5,500 | $561,422.05 | 58,117 | |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Jan 22, 2026 | Sell | $110.16 | 14,300 | $1,575,288.00 | 62,436 | |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Jan 21, 2026 | Sell | $109.84 | 700 | $76,888.00 | 62,436 | |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Jan 6, 2026 | Sell | $97.49 | 2,589 | $251,559.68 | 62,436 | |
| Noci Darlene | NUVL | Chief Development Officer | Jan 6, 2026 | Sell | $97.49 | 3,181 | $309,081.30 | 58,117 | |
| Balcom Alexandra | NUVL | Chief Financial Officer | Jan 6, 2026 | Sell | $97.49 | 3,181 | $309,081.30 | 81,733 | |
| Turner Christopher Durant | NUVL | Chief Medical Officer | Jan 6, 2026 | Sell | $97.49 | 3,181 | $309,081.30 | 55,355 | |
| Porter James Richard | NUVL | President and CEO | Jan 6, 2026 | Sell | $97.49 | 9,543 | $927,243.90 | 284,209 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 26, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 26, 2026 · 100% conf.
1D
-0.92%
$102.98
5D
-5.29%
$98.43
20D
+0.13%
$104.06
8-K
0001861560false00018615602026-02-262026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026
NUVALENT, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-40671
81-5112298
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Nuvalent, Inc. One Broadway, 14th Floor, Cambridge, Massachusetts 02142 (Address of principal executive offices, including zip code) (857) 357-7000 (Registrant’s telephone number, including area code) Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trade Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share
NUVL
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On February 26, 2026, Nuvalent, Inc. announced its financial results for the quarter and year ended December 31, 2025, and other corporate updates. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:
Exhibit No.
Description
99.1
Press Release issued by Nuvalent, Inc. on February 26, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Nuvalent, Inc.
Date: February 26, 2026
By:
/s/ James R. Porter, Ph.D.
James R. Porter, Ph.D.
President and Chief Executive Officer
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 14, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLJan 14, 2026 · 100% conf.
1D
-0.92%
$102.98
5D
-5.29%
$98.43
20D
+0.13%
$104.06
8-K
false000186156000018615602024-01-082024-01-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026
NUVALENT, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-40671
81-5112298
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Nuvalent, Inc. One Broadway, 14th Floor, Cambridge, Massachusetts 02142 (Address of principal executive offices, including zip code) (857) 357-7000 (Registrant’s telephone number, including area code) Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trade Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share
NUVL
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.
Results of Operations and Financial Condition.
On January 12, 2026, Nuvalent, Inc. (the “Company”) issued a press release in which it reported a preliminary estimate that, as of December 31, 2025, it had approximately $1.4 billion in cash, cash equivalents and marketable securities. This amount is a preliminary, unaudited estimate only as of January 12, 2026, is subject to completion of the Company’s year-end financial closing procedures that could result in changes to the amount, and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the Company’s estimate of its cash, cash equivalents and marketable securities as of December 31, 2025. Any forward-looking statements in this Current Report on Form 8-K are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form 8-K, including the risks and uncertainties described in greater detail in the section entitled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, as well as any prior and subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the Company’s views only as of the date of this Current Report on Form 8-K and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:
Exhibit No.
Description
99.1
Press Release issued by Nuvalent, Inc. on January 12, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL d
2025 Q3 Q3 2025 Earnings
8-K Oct 30, 2025
Q3 2025 Earnings
8-KOct 30, 2025
8-K
false0001861560October 30, 202500018615602025-10-302025-10-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025
NUVALENT, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-40671
81-5112298
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
Nuvalent, Inc. One Broadway, 14th Floor, Cambridge, Massachusetts 02142 (Address of principal executive offices, including zip code) (857) 357-7000 (Registrant’s telephone number, including area code) Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trade Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share
NUVL
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On October 30, 2025, Nuvalent, Inc. announced its financial results for the quarter ended September 30, 2025, and other corporate updates. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:
Exhibit No.
Description
99.1
Press Release issued by Nuvalent, Inc. on October 30, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Nuvalent, Inc.
Date:
October 30, 2025
By:
/s/ James R. Porter, Ph.D.
James R. Porter, Ph.D. President and Chief Executive Officer
Compare NUVL vs Leading Stocks
See how NUVL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NUVL Nuvalent Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.